Evaluation of the Cytotoxicity of Cationic Polymers on Glioblastoma Cancer Stem Cells.
cancer stem cells
cationic polymers
cytotoxicity
glioblastoma
polyethylenimine
Journal
Journal of functional biomaterials
ISSN: 2079-4983
Titre abrégé: J Funct Biomater
Pays: Switzerland
ID NLM: 101570734
Informations de publication
Date de publication:
28 Dec 2022
28 Dec 2022
Historique:
received:
21
11
2022
revised:
16
12
2022
accepted:
20
12
2022
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
Cationic polymers such as polyethylenimine (PEI) have found a pervasive place in laboratories across the world as gene delivery agents. However, their applications are not limited to this role, having found a place as delivery agents for drugs, in complexes known as polymer-drug conjugates (PDCs). Yet a potentially underexplored domain of research is in their inherent potential as anti-cancer therapeutic agents, which has been indicated by several studies. Even more interesting is the recent observation that certain polycations may present a significantly greater toxicity towards the clinically important cancer stem cell (CSC) niche than towards more differentiated bulk tumour cells. These cells, which possess the stem-like characteristics of self-renewal and differentiation, are highly implicated in cancer drug resistance, tumour recurrence and poor clinical prognosis. The search for compounds which may target and eliminate these cells is thus of great research interest. As such, the observation in our previous study on a PEI-based PDC which showed a considerably higher toxicity of PEI towards glioblastoma CSCs (GSCs) than on more differentiated glioma (U87) cells led us to investigate other cationic polymers for a similar effect. The evaluation of the toxicity of a range of different types of polycations, and an investigation into the potential source of GSC's sensitivity to such compounds is thus described.
Identifiants
pubmed: 36662064
pii: jfb14010017
doi: 10.3390/jfb14010017
pmc: PMC9862959
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : ARCPJA32020060002306
Organisme : Agence Nationale de la Recherche
ID : ANR-10-IDEX-0002
Organisme : Agence Nationale de la Recherche
ID : ANR-20-SFRI-0012
Références
J Drug Target. 2002 Mar;10(2):161-73
pubmed: 12074543
Bioorg Med Chem Lett. 2018 Apr 15;28(7):1161-1165
pubmed: 29534927
Cancers (Basel). 2022 Oct 15;14(20):
pubmed: 36291841
Bioconjug Chem. 2003 May-Jun;14(3):581-7
pubmed: 12757382
BMC Cancer. 2015;15 Suppl 1:S1
pubmed: 25708542
Pharm Res. 1999 Aug;16(8):1273-9
pubmed: 10468031
Chem Biol Interact. 2022 Nov 1;367:110167
pubmed: 36087816
Nat Rev Drug Discov. 2019 Apr;18(4):273-294
pubmed: 30542076
J Pathol. 2019 Apr;247(5):708-718
pubmed: 30570140
Chem Soc Rev. 2012 Nov 7;41(21):7147-94
pubmed: 22885409
Cancer Res. 2005 Sep 15;65(18):8079-84
pubmed: 16166279
J Biol Chem. 1986 Nov 25;261(33):15725-33
pubmed: 3782085
Polymers (Basel). 2021 Nov 09;13(22):
pubmed: 34833170
Chemistry. 2018 Feb 26;24(12):2806-2814
pubmed: 29034997
J Nanobiotechnology. 2019 May 4;17(1):59
pubmed: 31054582
Int J Mol Sci. 2022 May 19;23(10):
pubmed: 35628503
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Cancers (Basel). 2021 May 27;13(11):
pubmed: 34071918
Adv Drug Deliv Rev. 2021 Nov;178:113908
pubmed: 34390777
Int J Pharm. 2003 Feb 18;252(1-2):263-6
pubmed: 12550802
Life Sci. 2019 Oct 1;234:116781
pubmed: 31430455
Biochem Soc Trans. 2014 Jun;42(3):689-95
pubmed: 24849238
Theranostics. 2016 Aug 07;6(11):1887-98
pubmed: 27570558
Biochem Biophys Res Commun. 2010 Oct 22;401(3):480-6
pubmed: 20875394
Int J Biochem Cell Biol. 2019 Apr;109:90-104
pubmed: 30743057
Mol Pharm. 2010 Jun 7;7(3):727-37
pubmed: 20429563
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12349-54
pubmed: 8901584
Int J Pharm. 2017 Apr 15;521(1-2):249-258
pubmed: 28232268
Int J Mol Sci. 2018 Nov 05;19(11):
pubmed: 30400637
J Control Release. 2003 Apr 14;89(1):113-25
pubmed: 12695067
FEBS J. 2014 Nov;281(22):4993-5008
pubmed: 25284049
Cancer Res. 1989 Apr 15;49(8):2096-103
pubmed: 2522816
Breast Cancer (Dove Med Press). 2022 Apr 08;14:71-83
pubmed: 35422657
Angew Chem Int Ed Engl. 2019 Jul 15;58(29):9912-9916
pubmed: 31119851
J Gene Med. 2004 Jul;6(7):769-76
pubmed: 15241784
Biochem Soc Trans. 2007 Aug;35(Pt 4):788-93
pubmed: 17635149
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
pubmed: 7638184
Food Chem. 2016 Jan 1;190:1174-1181
pubmed: 26213092
Sci Rep. 2016 Apr 14;6:24506
pubmed: 27074905
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Nature. 2007 Apr 26;446(7139):1030-7
pubmed: 17460664
Carbohydr Res. 1986 Aug 15;151:403-8
pubmed: 3768901
Proc Natl Acad Sci U S A. 1985 May;82(10):3197-201
pubmed: 3858816
Clin Cancer Res. 2010 May 15;16(10):2715-28
pubmed: 20442299
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Biomaterials. 2003 Mar;24(7):1121-31
pubmed: 12527253
FEBS J. 2019 Aug;286(15):2870-2882
pubmed: 31230410
Pharm Res. 1996 Jul;13(7):1038-42
pubmed: 8842041
J Neurooncol. 1986;4(1):43-8
pubmed: 3746384
Bioconjug Chem. 2016 Aug 17;27(8):1942-8
pubmed: 27459208
Radiol Oncol. 2013 Oct 08;47(4):330-7
pubmed: 24294177
J Nanobiotechnology. 2021 Sep 27;19(1):292
pubmed: 34579715
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046